Results for tag: "Fasenra"

Fasenra is a biologic drug used to treat severe asthma and chronic obstructive pulmonary disease (COPD). It is a monoclonal antibody that works by targeting and blocking the action of interleukin-5 (IL-5), a cytokine that plays a role in the inflammation associated with these conditions. It is administered as an injection under the skin, and is typically used in combination with other asthma and COPD medications. Fasenra is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2017. It is currently marketed by AstraZeneca, and is available in the United States, Canada, and several other countries. The Fasenra market is highly competitive, with several other biologic drugs available to treat severe asthma and COPD. These include GlaxoSmithKline's Nucala, Teva's Cinqair, and Novartis' Xolair. Other companies in the market include Sanofi, Regeneron, and Biogen. Show Less Read more